28 citations
,
March 2014 in “International Journal of Nanomedicine”
This study developed lipid nanoparticles for delivering minoxidil and finasteride to the dermis and hair follicles, showing stability and a desired prolonged release, though with low skin penetration levels.
April 2018 in “Journal of Investigative Dermatology”
This study suggests that the Leptin receptor may serve as a novel cell surface marker for dermal papilla cells, potentially aiding future isolation and research efforts in hair follicle regeneration studies.
Oral minoxidil combined with finasteride can improve hair density, but long-term safety is uncertain due to potential side effects like heart and kidney issues. Users report mixed experiences, with some experiencing side effects and others finding it effective for hair maintenance.
RU58841 is discussed as a potential hair loss treatment, with comparisons to finasteride. There is interest in leaked trial data, but no official clinical validation or approval for RU58841.
PP405 shows potential for hair growth by increasing terminal hair and converting vellus hairs, but results are modest and more waiting is needed. It complements existing treatments like minoxidil and finasteride, but won't replace them.
The user is concerned about potential scarring from using a 1.5mm dermastamp for hair loss treatment and is advised to use shallower depths (0.5-0.75mm) and reduce frequency to avoid damage. They also use topical minoxidil and finasteride, and plan to stop stamping temporarily to assess changes.
PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.